Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
17/12/2024 11:37
Dec 17 (Reuters) - Affimed NV A28A.F :
* AFFIMED REPORTS POSITIVE CLINICAL UPDATE ON
AFM24/ATEZOLIZUMAB
COMBINATION THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC)
* AFFIMED NV - AFM24 AND ATEZOLIZUMAB SHOW MANAGEABLE SIDE
EFFECT
PROFILE
Source text: ID:nGNX4wyKm9
Further company coverage: A28A.F
Recent news on Affimed NV
See all newsBrief: Affimed Announces Receipt Of Nasdaq Delisting Notice
Brief: Affimed Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
Brief: Affimed NV Files For Common Stock Offering Of Up To $20 Million - SEC Filing
Brief: Affimed NV Files For Mixed Shelf Offering Of Up To $20 Million